Skip to main content

Published locations for SRA737 + anti–PD-L1 therapy and low-dose gemcitabine shows early promise for SCLC

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. SRA737 + anti–PD-L1 therapy and low-dose gemcitabine shows early promise for SCLC

User login

  • Reset your password
  • /content/sra737-anti-pd-l1-therapy-and-low-dose-gemcitabine-shows-early-promise-sclc
  • /fedprac/article/199928/lung-cancer/sra737-anti-pd-l1-therapy-and-low-dose-gemcitabine-shows-early
  • /oncologypractice/article/199928/lung-cancer/sra737-anti-pd-l1-therapy-and-low-dose-gemcitabine-shows
  • /fedprac/avaho/article/199928/lung-cancer/sra737-anti-pd-l1-therapy-and-low-dose-gemcitabine-shows
  • /hematology-oncology/article/199928/lung-cancer/sra737-anti-pd-l1-therapy-and-low-dose-gemcitabine